


medicines
patent
pool



medicines
patent
pool




IMPLEMENTATION OF DACLATASVIR LICENCES

DEVELOPMENT REPORT

2017–2020

7 daclatasvir sublicensee agreements





 Companies approved

Note: Each triangle represents a manufacturer and timelines represent date of filing

**4 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG, OF WHICH:
4 COMPANIES ARE READY TO SUPPLY**

Licensees Approved*: Cipla, Hetero, Laurus, Mylan

Generic DAC has been approved in **34** countries and filed in additional **18** countries
Filings have occurred in **52** countries overall where **72.1%** PLHCV[^] reside in the licensed territory[#]

APPROVED (34) 65.3% PLHCV

Benin	Guyana	Pakistan
Burkina Faso	India	Philippines
Cambodia	Indonesia	Tanzania
Cameroon	Kazakhstan	Turkmenistan
Chad	Kyrgyzstan	Uganda
Congo, Dem. Rep.	Liberia	Ukraine
Congo, Rep.	Malawi	Uzbekistan
Côte d'Ivoire	Malaysia	Vietnam
Dominican Republic	Mongolia	Zambia
Ethiopia	Myanmar	Zimbabwe
Gabon	Nicaragua	
Ghana	Nigeria	

FILED (18) 6.8% PLHCV

Azerbaijan	Mozambique
Bolivia	Namibia
Botswana	Nepal
Burundi	Paraguay
Georgia	Rwanda
Guatemala	Senegal
Haiti	Suriname
Honduras	Thailand
Kenya	Togo


- Vis-à-vis last update (Q3-20)
- Countries where DAC 30mg & 60mg has been sold indicated in **bold type**

[^] People living with Hepatitis

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

[#] [MPP-BMS DAC licence agreement](#)

MPP licensees have sold more than **1 Million** treatments* of generic DAC 30/60mg across **34** countries, in which **65.3%** of PLHCV[^] reside in the licensed territory[#]




Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

[^] People living with Hepatitis



[#] [MPP-BMS DAC licence agreement](#)

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)



*Non-identified countries are a result of sales made through procurement agencies

** Others include countries in which fewer than 5,000 treatments were sold: Nigeria, Azerbaijan, Cuba, Kyrgyzstan, Armenia, Tanzania, Nepal, South Africa, Bangladesh, Argentina, Mongolia, Bolivia, Moldova, Tajikistan, Cameroon, Congo, Laos, Phillipines, Sri Lanka, Timor-Leste, Zimbabwe, Mauritius



*Note: 1 HCV treatment = 12 weeks therapy (3 packs)



 Companies approved

***Note:** Each triangle represents a manufacturer and timelines represent date of filing*

**2 MPP LICENSEES HAVE DEVELOPED DAC/SOF AND
ONLY MYLAN IS READY TO SUPPLY***

Licensees Approved*: Cipla (co-pack), Mylan

Generic DAC/SOF has been approved in **10** countries and filed in additional **9** countries
Filings have occurred where **52.2%** of PLHCV [^] reside in the licensed territory [#]

APPROVED (10) 28.7% PLHCV

Côte d'Ivoire

Myanmar

Ethiopia

Nicaragua

Ghana

Nigeria

India

Uganda

Malawi

Zambia

FILED (9) 23.4% PLHCV

Guyana

Suriname

Kenya

Tanzania

Namibia

Vietnam

Pakistan

Zimbabwe

Paraguay


- New filings and approvals in **green** vis-à-vis last update (Q3-20)
- Countries where DAC/SOF has been sold indicated in **bold type**


[^] People living with Hepatitis

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

[#] [MPP-BMS DAC licence agreement](#)

MPP licensees have supplied more than **97,000** packs* of generic DAC/SOF across:
Cambodia, Ethiopia, India, Laos, Myanmar, Nigeria, South Africa, Uganda, Vietnam





THANK YOU